- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Patent holdings for IPC class A61P 1/16
Total number of patents in this class: 7038
10-year publication summary
|
200
|
239
|
289
|
512
|
602
|
720
|
836
|
916
|
771
|
176
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
73 |
| Gilead Sciences, Inc. | 1879 |
57 |
| Genfit | 257 |
54 |
| Daiichi Sankyo Company, Limited | 1829 |
51 |
| Takeda Pharmaceutical Company Limited | 2961 |
47 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
46 |
| Eli Lilly and Company | 3645 |
41 |
| Osaka University | 3143 |
40 |
| Albireo AB | 157 |
39 |
| Bristol-myers Squibb Company | 5080 |
37 |
| The Regents of the University of California | 18943 |
35 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
32 |
| InterCept Pharmaceuticals, Inc. | 224 |
32 |
| Pfizer Inc. | 3322 |
30 |
| Banyu Pharmaceutical Co., Ltd. | 107 |
29 |
| Kowa Company, Ltd. | 1172 |
29 |
| Boehringer Ingelheim International GmbH | 4629 |
28 |
| Vertex Pharmaceuticals Incorporated | 1581 |
26 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
26 |
| The University of Tokyo | 3903 |
26 |
| Other owners | 6260 |